FDA alerts providers to recall of drug to treat serious bacterial infections
The Food and Drug Administration yesterday alerted pharmacy and nursing professionals to a voluntary recall of seven lots of an injectable drug used to treat certain serious bacterial infections, which may contain glass particulate matter. The Teva Pharmaceuticals Amikacin Sulfate Injection USP vials were distributed nationwide through wholesalers, retailers and pharmacies. Anyone with an existing inventory of the recalled lots should stop using and quarantine the product immediately, FDA said. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of the product to the FDA's MedWatch program.
Related News Articles
Headline
Angela Hewlett, M.D., professor of infectious diseases at the University of Nebraska Medical Center and medical director of the Nebraska Biocontainment Unit,…
Headline
The Food and Drug Administration June 16 announced that a nationwide shortage of stereotactic breast biopsy needles is expected to last through the end of…
Headline
The Administration for Strategic Preparedness and Response June 16 announced the launch of the Digital Stockpile and Manufacturing Response Network Challenge,…
Headline
Stormee Williams, M.D., senior vice president and chief health equity officer at Children’s Health, shares how her team is identifying food insecurity, why…
Headline
President Trump signed an executive order May 29 that directs the Centers for Disease Control and Prevention and the Advisory Committee on Immunization…
Headline
The Centers for Disease Control and Prevention today released a report highlighting data on patients hospitalized during a 2025 measles outbreak centered in…